Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116746) titled 'Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Arthrosi Therapeutics
Condition:
Gout
Gouty Arthritis
Hyperuricemia
Gout Chronic
Refractory Gout
Uncontrolled Gout
Tophaceous Gout
Intervention:
Drug: AR882 75 mg
Drug: XOI Low Dose
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 2025
Target Sample Size: 25
To know more, visit...